Promising Immunotherapy Results for Metastatic Breast Cancer

Overview of Breast Cancer Statistics

At the ESMO 2018 Congress, researchers shared encouraging findings from an immunotherapy trial focused on patients diagnosed with aggressive metastatic breast cancer. According to statistics from the World Cancer Research Fund, breast cancer is the most prevalent cancer among women, with over two million new cases reported in 2018.

Understanding Breast Cancer Types

Breast cancer encompasses various types. Correctly identifying the specific tumor type is crucial for doctors to determine the most effective treatment regimen. A majority of breast cancers exhibit receptors for hormones such as estrogen or progesterone, or they produce a protein called HER2. These tumors typically respond well to hormone therapies or treatments targeting HER2.

However, there are breast cancers that lack these characteristics, known as triple-negative breast cancer (TNBC). Although less common, TNBC is recognized as the most aggressive form and frequently affects younger women. When a tumor metastasizes, spreading beyond the breast to other parts of the body, it is classified as metastatic breast cancer. For patients diagnosed with metastatic TNBC, the average survival period is estimated to be between 12 to 15 months.

Challenges in Treating Triple-Negative Breast Cancer

The primary treatment for TNBC is chemotherapy, which aims to destroy cancer cells. Unfortunately, many patients develop resistance to chemotherapy within a few months, complicating their treatment options. In this context, immunotherapy drugs have emerged as a potential alternative by stimulating the body’s immune system to combat cancer cells. A combination of chemotherapy and immunotherapy may provide a new avenue for treatment.

IMpassion130 Trial: A Groundbreaking Investigation

The IMpassion130 trial is an international study exploring the efficacy of combining the chemotherapy drug nab-paclitaxel with the immunotherapy drug atezolizumab in patients with metastatic TNBC. Atezolizumab is designed to target a protein known as PD-L1 on tumor cells, which suppresses immune system activity. By inhibiting PD-L1, atezolizumab effectively “releases the brake” on the immune system, allowing it to attack cancer cells. Drugs of this nature are classified as “immune checkpoint inhibitors.”

Key Findings from the IMpassion130 Trial

Researchers presented interim results of the IMpassion130 trial at the ESMO 2018 Congress, which involved 902 women diagnosed with metastatic TNBC. Participants were assigned to receive standard chemotherapy (nab-paclitaxel) in conjunction with atezolizumab or a placebo. The study aimed to evaluate whether this combination could slow cancer progression (progression-free survival) and enhance overall survival.

The findings indicated that in the overall study population, the average progression-free survival was 7.2 months for the combination therapy group compared to 5.5 months for the chemotherapy-only group. In the subgroup of patients with PD-L1 positive tumors, progression-free survival was notably better at 7.5 months for the combination therapy versus 5.0 months for chemotherapy alone.

In terms of overall survival, the entire study population experienced an average of 21.3 months with combination therapy compared to 17.6 months with chemotherapy alone, a difference that did not reach statistical significance. However, among patients with PD-L1 positive tumors, average overall survival increased to 25 months with combination therapy compared to 15.5 months with chemotherapy alone, achieving statistical significance.

Tolerability and Future Implications

The combination therapy was generally well tolerated, with most side effects attributed to chemotherapy rather than the immunotherapy drug. Researchers expressed optimism regarding these promising interim results from the IMpassion130 trial, noting that immune therapy alongside standard chemotherapy extended survival by 10 months for patients with PD-L1 expressing tumors.

Lead investigator Professor Peter Schmid remarked that “this combination should become a new treatment option for patients with metastatic TNBC,” signaling a potential shift in treatment protocols for these patients.

Ongoing Research and Future Trials

Dr. Marleen Kok from The Netherlands Cancer Institute in Amsterdam echoed the significance of the observed overall survival improvements with combination therapy, predicting that it will likely alter the treatment landscape for patients with metastatic TNBC. She also highlighted the existence of several ongoing trials examining other combinations of chemotherapy and immunotherapy, both in metastatic breast cancer and early-stage breast cancer patients, which will be critical in identifying optimal treatment strategies.

Written by Julie McShane, Medical Writer
Reference: Press release: Some patients with metastatic triple-negative breast cancer live longer with immunotherapy (ESMO 2018 Press Release) https://www.esmo.org/Press-Office/Press-Releases/IMpassion130-atezolizumab-nab-pac-triple-negative-breast-cancer-Schmid
Relevant topics that may be of interest:
What’s the link between success of cancer immunotherapy and gut bacteria?
The future of immunotherapy for glioblastoma
Can an immunotherapy cream prevent skin cancer developing after sun damage?
Can allergy immunotherapy desensitize patients allergic to wheat?
Remarkable outcomes for leukemia with chemo and immunotherapy combination